Hypereosinophilic syndromes are a varied group of rare blood diseases. The primary factor they have in common is a very high level of a type of white blood cell called eosinophils. While usually an essential part of the immune system, too many eosinophils in various parts of the body can cause organ damage. These syndromes […]
NEWTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) — Auron Therapeutics, a platform-based, product-driven biotechnology company focused on developing novel cancer therapies that target cellular plasticity, today announced the members of its scientific advisory board (SAB), comprised of distinguished physician-scientists, clinical investigators, and research & development veterans from world-leading cancer centers and biopharmaceutical companies. The most […]
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
V. Subbiah reports research funding from Novartis, Eli Lilly/Loxo Oncology, and Blueprint Medicines to conduct clinical trials; other grant support for clinical trials from AbbVie, Agensys, Inc, Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicines Corporation, Boston Biomedical, Inc, Boston Pharmaceuticals, Celgene Corporation, D3 Bio, Inc, Dragonfly Therapeutics, Inc, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Inc, […]
Auron Establishes Premier Scientific Advisory Board to Support the Advancement of its AI-Powered Platform and Pipeline Targeting Cellular Plasticity in Cancer News Home Tuesday, August 01, 2023 07:30 AM | GlobeNewswire via QuoteMedia Auron Establishes Premier Scientific Advisory Board to Support the Advancement of its AI-Powered Platform and Pipeline Targeting Cellular Plasticity in Cancer Advisory […]
“Cigarette smoking is the leading cause of lung cancer. Tobacco smoke contains numerous carcinogens (cancer-causing substances) that damage the cells lining the lungs. Smokers are at a much higher risk of developing lung cancer compared to non-smokers. Additionally, exposure to secondhand smoke can also increase the risk, albeit to a lesser extent,” says Dr Singh. […]
Share Link Copy this link, or click below to email it to a friend Email this content or copy the link directly: https://avmajournals.avma.org/view/journals/javma/aop/javma.23.05.0284/javma.23.05.0284.xml The link was not copied. Your current browser may not support copying via this button. Link copied successfully Copy link
Lund, July 31 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into a clinical trial collaboration agreement with Stichting Haemato-Oncologie Volwassenen Netherland (HOVON) and Stichting Oncode Institute (Oncode) for the upcoming clinical proof-of-concept trial of tasquinimod in myelofibrosis. HOVON will be the legal sponsor of the trial, Oncode the main financier […]
Introduction Pseudomonas aeruginosa (PA) is an opportunistic pathogen with combined antibiotic resistance, multifactorial virulence, and dynamic over-adaptive capacity that is particularly difficult to eliminate from patients and is an important cause of nosocomial infections that can be life-threatening in critically ill and immunocompromised patients. The mortality rate of PA bloodstream infection (BSI) has been reported […]
